1
|
Tian M, Du W, Yang S, Liao Q, Guo F, Li S. Application and progress of hyperbaric oxygen therapy in cardiovascular diseases. Med Gas Res 2025; 15:427-434. [PMID: 40251023 PMCID: PMC12054664 DOI: 10.4103/mgr.medgasres-d-24-00107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2024] [Revised: 11/14/2024] [Accepted: 12/12/2024] [Indexed: 04/20/2025] Open
Abstract
Cardiovascular diseases remain the leading cause of death worldwide, underscoring the urgent need for additional therapeutic strategies to reduce their mortality rates. This review systematically outlines the historical development and recent advances of hyperbaric oxygen therapy in cardiovascular diseases, with a focus on its therapeutic mechanisms and clinical outcomes. Hyperbaric oxygen therapy enhances oxygen delivery to ischemic and reperfused tissues, promotes angiogenesis, and significantly suppresses oxidative stress, inflammatory cascades, and cardiomyocyte apoptosis, demonstrating multifaceted therapeutic potential in cardiovascular conditions. Specifically, hyperbaric oxygen therapy combined with reperfusion strategies has been shown to markedly improve left ventricular ejection fraction in acute myocardial infarction. In heart failure, it facilitates myocardial repair and enhances cardiac function. For arrhythmias, hyperbaric oxygen therapy effectively reduces the frequency and duration of premature ventricular contractions and paroxysmal tachycardia, while mitigating the risk of neurological complications following atrial fibrillation ablation. Furthermore, hyperbaric oxygen therapy preconditioning in cardiac surgery has demonstrated improvements in left ventricular stroke work, reductions in postoperative myocardial injury, and a decrease in related complications. Despite its promising applications, the widespread adoption of hyperbaric oxygen therapy remains hindered by the lack of standardized treatment protocols and high-quality evidence from rigorous clinical trials. In conclusion, this review underscores the potential value of hyperbaric oxygen therapy in the cardiovascular domain while highlighting the need for further optimization of therapeutic parameters and exploration of its synergistic effects with conventional therapies to provide clearer guidance for clinical implementation.
Collapse
Affiliation(s)
- Menglin Tian
- Key Laboratory of Cardiovascular Disease of Yunnan Province, Clinical Medicine Center for Cardiovascular Disease of Yunnan Province, Department of Cardiology, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China
| | - Wenyin Du
- Key Laboratory of Cardiovascular Disease of Yunnan Province, Clinical Medicine Center for Cardiovascular Disease of Yunnan Province, Department of Cardiology, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China
| | - Sen Yang
- Key Laboratory of Cardiovascular Disease of Yunnan Province, Clinical Medicine Center for Cardiovascular Disease of Yunnan Province, Department of Cardiology, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China
| | - Qiwei Liao
- Key Laboratory of Cardiovascular Disease of Yunnan Province, Clinical Medicine Center for Cardiovascular Disease of Yunnan Province, Department of Cardiology, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China
| | - Fuding Guo
- Key Laboratory of Cardiovascular Disease of Yunnan Province, Clinical Medicine Center for Cardiovascular Disease of Yunnan Province, Department of Cardiology, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China
| | - Shaolong Li
- Key Laboratory of Cardiovascular Disease of Yunnan Province, Clinical Medicine Center for Cardiovascular Disease of Yunnan Province, Department of Cardiology, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China
| |
Collapse
|
2
|
Shih RD, Tomaszewski CA, Kaji A, Diercks DB, Diercks DB, Anderson JD, Byyny R, Carpenter CR, Friedman BW, Gemme SR, Gerardo CJ, Godwin SA, Hatten BW, Haukoos JS, Kwok H, Lo BM, Mace SE, Mattu A, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Thompson JT, Tomaszewski CA, Trent S, Valente JH, Westafer LM, Wall SP, Yu Y, Finnell JT, Schulz T, Vandertulip K. A Critical Issue in the Management of Adult Patients Presenting to the Emergency Department With Acute Carbon Monoxide Poisoning: Approved by the ACEP Board of Directors January 22, 2025. Ann Emerg Med 2025; 85:e45-e59. [PMID: 40118649 DOI: 10.1016/j.annemergmed.2024.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2025]
|
3
|
Han Z, Shi S, Zhang Y, Yuan D, Xu Z, Gao Y. Clinical characteristics and the risk factors analysis in patients with delayed encephalopathy after acute carbon monoxide poisoning. Hum Exp Toxicol 2025; 44:9603271251332234. [PMID: 40180596 DOI: 10.1177/09603271251332234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2025]
Abstract
IntroductionAcute carbon monoxide poisoning (ACMP) remains a leading cause of morbidity and mortality from fatal inhaled poisoning. Delayed encephalopathy after ACMP (DEACMP) has become one of the most complex and serious complications.MethodsIn this research, an observational study was performed from January 2016 to December 2019 to investigate the potential relevant risk factors of DEACMP with data collected from Level 3 medical facilities located in Northern China. Within the 4-year data collection period, the final study cohort consisted of 240 (117 males, 123 females).ResultsUni-variable analysis identified older age, medical history of cerebrovascular accident, basic disease of diabetes, and longer duration of loss of consciousness as relevant factors for DEACMP; while multivariable logistic regression revealed that the older age (OR, 1.45; 95% CI, 1.25-1.69; P < 0.01), longer duration of loss of consciousness (OR, 1.39; 95% CI, 1.36-1.45; P < 0.01), and cerebrovascular accidents occurring (OR, 1.23; 95% CI, 1.03-1.47; P = 0.04) were independent predictors for DEACMP.DiscussionFurthermore, additional research is needed to testify to the relevance and to elucidate the potential pathogenesis, consequently determining the clinical guideline and approving the best prevention and treatment strategy for DEACMP.
Collapse
Affiliation(s)
- Ziang Han
- Department of Emergency Medicine, Medical Key Laboratory of Poisoning Diseases of Henan Province, The First Affiliated Hospital of Zhengzhou University, China
| | - Sumeng Shi
- East China Normal University, Shanghai, China
| | - Yan Zhang
- Department of Emergency Medicine, Medical Key Laboratory of Poisoning Diseases of Henan Province, The First Affiliated Hospital of Zhengzhou University, China
| | - Ding Yuan
- Department of Emergency Medicine, Medical Key Laboratory of Poisoning Diseases of Henan Province, The First Affiliated Hospital of Zhengzhou University, China
| | - Zhigao Xu
- Department of Emergency Medicine, Medical Key Laboratory of Poisoning Diseases of Henan Province, The First Affiliated Hospital of Zhengzhou University, China
| | - Yanxia Gao
- Department of Emergency Medicine, Medical Key Laboratory of Poisoning Diseases of Henan Province, The First Affiliated Hospital of Zhengzhou University, China
| |
Collapse
|